Injection Demos

Injecting ENBREL

ENBREL gives you and your patients the flexibility of multiple subcutaneous administration options.

ENBREL should be given as one 50-mg dose subcutaneously (SC) using either a 50-mg single-use prefilled syringe or a single-use prefilled Enbrel® (etanercept) SureClick® autoinjector. A 50-mg dose can also be given as two 25-mg SC injections using 25-mg single-use prefilled syringes or multiple-use vials. Sites for injection include the thigh, abdomen, or upper arm, and should be rotated. ENBREL should never be injected into areas where the skin is tender, bruised, red, or hard.

See Instructions for Use for detailed information on injection site selection and dose administration.

If a patient or caregiver is to administer ENBREL, the patient or caregiver should be instructed in injection techniques and how to measure and administer the correct dose (see Instructions for Use). The first injection should be performed under the supervision of a qualified health care professional. The patient's or caregiver's ability to inject subcutaneously should be assessed.

Patients and caregivers should be instructed in the technique as well as proper syringe and needle disposal, and be cautioned against reuse of needles and syringes. A puncture-resistant container for disposal of needles, syringes, and autoinjectors should be used. If the 25-mg multiple-use vial is intended for multiple use, additional syringes, needles, and alcohol swabs will be required.

Patients should be monitored for injection site reactions such as redness, rash, swelling, itching, or bruising. In controlled trials in patients with plaque psoriasis, 15% of patients treated with ENBREL developed injection site reactions during the first 3 months of treatment. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days.


How-to Videos and Demos

Review and share step-by-step instructions for patients.

Patients can inject ENBREL using a 50-mg/mL prefilled autoinjector.
Enbrel® SureClick® 50 mg/mL Autoinjector
Patients can inject ENBREL using a 50-mg/mL prefilled autoinjector. The Enbrel® SureClick® autoinjector is for single-use only.
Play
Patients can inject ENBREL using a prefilled syringe available in 50-mg/mL and 25-mg/0.5-mL dosage strengths.
ENBREL Single-Use Prefilled Syringe
Patients can inject ENBREL using a prefilled syringe available in 50-mg/mL and 25-mg/0.5-mL dosage strengths. The prefilled syringe is for single-use only.
Play
Enbrel 25-mg Multi-Use Vial, Free-hand Method may be used for treating some children with JIA.
ENBREL 25-mg Multi-Use Vial
Free-hand Method
For some children with JIA, one vial of ENBREL solution can be used for more than one dose. The free-hand method should be used for these children. You should not use the vial adapter method if you will be using the vial more than once.
Play
People who use a single vial of ENBREL for each dose may use the Enbrel 25-mg Vial Adapter device to assist with mixing and withdrawing ENBREL.
ENBREL 25-mg Vial Adapter Method
People who use a single vial of ENBREL for each dose may use the vial adapter device to assist with mixing and withdrawing ENBREL.
Play

 
INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Registered nurses are available by phone through ENBREL Support™ 7 days a week to answer patients' questions.
The Science of ENBREL

ENBREL blocks the activity of excess active tumor necrosis factor (TNF) to reduce the inflammation that causes plaques.

Discover the attributes
of ENBREL arrow

Gilbert had been dealing with his plaque psoriasis since just after high school and often had self-conscious feelings about his appearance.

Since starting on ENBREL, Gilbert has a new outlook on dealing with his symptoms.

"Before ENBREL, I was embarrassed even to go to a doctor and take off my shirt."
Home
Close